Dr. Ross's research focuses on designing, developing and testing vaccines for viral diseases that are often at the interface of zoonotic and human interface, such as influenza, dengue, chikungunya, respiratory syncytial virus and HIV. Dr. Ross' laboratory developed computationally-optimized broadly reactive antigen (COBRA) technology for the universal, rational design of vaccine candidates for influenza viruses. He and his laboratory have developed DNA, recombinant protein and virus-like particle (VLP) vaccines for pandemic and seasonal influenza pre-clinical and clinical research trials.